Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Medtronic (MDT)

NYSE: MDT · Medical Devices · Galway,

Our rating: Neutral

Neutral reaffirmed at $94.17, moderate conviction, September 4, 2026.

Breaks if: The neutral call turns Positive if Medtronic reports net margin above 15% and sustains revenue growth above 7% for two consecutive quarterly filings. It turns Cautious if revenue growth falls below 5% year-over-year, or if net margin drops below 11%, in either of the next two quarterly reports.

Key figures

Market value$127.8B
Revenue, last 12 months$37.5B
Net income, last 12 months$5.2B
Free cash flow, last 12 months$6.1B
Price to earnings24.4×
Free cash flow yield4.8%
Dividend yield2.9%
Operating margin18.1%
Return on equity10.7%
Beta to the S&P 5000.31
Volatility, annualized22.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
July 31, 2026$9.8B13.7%$1.14$1.3B
April 24, 2026$9.8B9.9%$0.97$2.1B
January 23, 2026$9.0B8.7%$0.89$2.3B
October 24, 2025$9.0B6.6%$1.07$457M
July 25, 2025$8.6B8.4%$0.81$584M
April 25, 2025$8.9B3.9%$0.82$2.1B
January 24, 2025$8.3B2.5%$1.01$2.1B
October 25, 2024$8.4B5.2%$0.99$554M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

9 ledger entries and 40 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.